Two Cases of Well Controlled Chronic Spontaneous Urticaria Triggered by the Moderna COVID-19 Vaccine

Cylie Alflen; Katheryn Birch; Ryan Shilian; Shan Shan Wu; Robert Hostoffer Jr

doi:10.1177/21526567211026271

Two Cases of Well Controlled Chronic Spontaneous Urticaria Triggered by the Moderna COVID-19 Vaccine

Allergy Rhinol (Providence). 2021 Jun 24:12:21526567211026271. doi: 10.1177/21526567211026271. eCollection 2021 Jan-Dec.

Authors

Cylie Alflen¹, Katheryn Birch², Ryan Shilian², Shan Shan Wu^{2

3}, Robert Hostoffer Jr^{2

3}

Affiliations

¹ Lake Erie College of Osteopathic Medicine, Erie, Pennsylvania.
² Allergy/Immunology Associates Inc., Mayfield Heights, Ohio.
³ Cleveland Medical Center, University Hospitals, Cleveland, Ohio.

Abstract

Chronic spontaneous urticaria (CSU, chronic idiopathic urticaria) is a clinical diagnosis characterized by recurrent urticaria of unknown origin, with or without angioedema, that occurs for six weeks or longer. Management of CSU includes a second-generation H1 antihistamine and/or elimination of exacerbating factors. If initial treatment is unsuccessful, trials of first generation H1 antihistamine, H2 blocking antihistamine, leukotriene-receptor antagonist, anti-inflammatory or immunosuppressive agents may be administered. Exacerbating factors include stress, environmental conditions, medications, physical stimuli, and infections. We report the first two cases of a COVID-19 vaccine triggered relapse of CSU that was previously well controlled on therapy.

Keywords: COVID-19 vaccine; CSU; chronic spontaneous urticaria.

Publication types

Case Reports